Antiphospholipid syndrome in miscarriage

Abstract

Purpose: the frequency of antiphospholipid in patients with reproductive failures was defined. The algorithm of the treatment of these patients was presented. Materials and methods: the study included 2150 patients: 1650 with a history of the repeated pregnancy losses; 450 with sterility and 50 healphy women. Results: the high levels of AFA were founded in 24 % of patients with spontaneous abortions and in 20 % of patients with sterility. Conclusion: Pregravid preparation and permanent monitoring the state of patients reduce frequency of unfavorable ends of pregnancy effectively.

Keywords

antiphospholipid syndrome / recurrent miscarriage / anti-beta glycoprotein I antibodies

References

[1] Агаджанова А. А. Основные подходы к комплексной терапии АФС в клинике невынашивания беременности. Акушерство и гинекология. 1999; 3 (5): 8-6.

[2] Аржанова О. Н., Шляхтенко Т. Н., Сельков С. А. Роль антифосфолипидных антител (АФА) в патогенезе невынашивания беременности. Журнал акушерства и женских болезней. 2002; (2): 22-18.

[3] Лапин С. В. Иммунологическая лабораторная диагностика аутоиммунных заболеваний. СПб.: Человек; 2010.

[4] Насонов Е. Л. Антифосфолипидный синдром. М.: Литерра; 2004.

[5] Сельков С. А., Соколов Д. И., Чепанов С. В. Иммунорегуляторные эффекты иммуноглобулинов для внутривенного введения. Медицинская иммунология. 2013; 15 (1): 12-5.

[6] Сельков С. А., Зайнулина М. С., Чугунова А. А., Селютин А. В., Михайлова В. А., Чепанов С. В. Клинико-иммунологическое обоснование использования иммуноглобулинов для внутривенного введения в лечении антифосфолипидного синдрома при беременности. Журнал акушерства и женских болезней. 2012; 61 (2): 11-5.

[7] Сидельникова В. М. Подготовка и ведение беременности у женщин с привычным невынашиванием. М.: МЕДпресс; 2011.

[8] Biggioggero M., Meroni P. L. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun. Rev. 2010; 9 (5): 304-299.

[9] Buckingham K. L., Chamley L. W. A critical assessment of the role of antiphospholipid antibodies in infertility. J. Reprod. Immunol. 2009; 80 (1-2): 132-45.

[10] Clark C., Laskin C., Spitzer K. Anticardiolipin antibodies and recurrent early pregnancy loss: a century of equivocal evidence. Hum. Reprod. Update. 2012; 18 (5): 474-84.

[11] Faden D., Tincani A., Tanzi P., Spatola L., Lojacono A., Tarantini M., Balestrieri G. Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Anti-beta2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol. 1997; 73 (1):37-42.

[12] Forastiero R., Martinuzzo M., Pombo D., Puente D., Rossi A., Bonaccorso S., Aversa L. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J. Thromb. Haemost. 2005; 3 (6): 1231-8.

[13] Galli M., Luciani D., Bertolini G., Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101 (5): 1827-32.

[14] Hughes G. R. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br. Med. J. (Clin. Res. Ed). 1983; 287 (399): 1088-9.

[15] Laat B. de, Ronald H. W., Rolf T., Phillip de Groot. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. Journal Thromb. Haemost. 2009; 7 (11): 1767-73.

[16] Laat B. de, Derksen R. H., Groot P. G. de. High-avidity anti-beta glycoprotein I antibodies highly correlate with thrombosis in contrast to low-avidity anti-beta glycoprotein I antibodies. J. Thromb. Haemost. 2006; 4 (7): 1619-21.

[17] Lakos G., Favaloro E. J., Harris E. N., Meroni P. L., Tincani A., Wong R. C., Pierangeli S. S. International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum. 2012; 64 (1): 10-1.

[18] Meroni P. L. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res. Ther. 2014; 16 (2): 209.

[19] Miyakis S., Lockshin M. D., Atsumi T., Branch D. W., Brey R. L., Cervera R., Derksen R. H., De Groot P. G., Koike T., Meroni P. L. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. Journal Thromb. Haemost. 2006; 13: 295-306.

[20] Naess I. A., Christiansen S. C., Cannegeiter S. C., Rosendaal F. K., Hammerstoem J. A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J. Thromb. Haemost. 2006; 4 (1): 44-9.

[21] Pengo V., Tripodi A., Reber G. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant. Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J. Thromb. Haemost. 2009; 7 (10): 1737-40.

[22] Pierangeli S. S., Harris E. N. An antiphospholipid wet workshop: 7th International Symposium on Antiphospholipid Antibodies. J. Rheumatol. 1998; 25 (1): 156-60.

[23] Rand J. H. Molecular Pathogenesis of the Antiphospholipid Syndrome. Circ. Res. 2002; 90 (1): 37-29.

[24] Ronda N., Lockwood C., Jayne D., Arora Y. K. Binding and internalization of human IgG by living cultured endothelial cells. Clin. Exp. Immunol. 1997; 109 (1): 211-6.

[25] Stephenson M. D., Kutten W. H., Purkiss S. Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebo-controlled trial. Hum. Reprod. 2010; 25 (9): 2203-9.

[26] Urbanus R. T., Groot P. G. de. Antiphospholipid antibodies - we are not quite there yet. Blood Rev. 2011; 25 (N): 106-97.

[27] Wolf F. De. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am. J. Obstet. Gynecol. 1982; 142 (7): 829-34.

[28] Wong R. C. W., Favaloro E. J. Clinical features, diagnosis, and management of the antiphospholipid syndrome. Semin. Thromb. Hemost. 2008; 34 (3): 295-304.

RIGHTS & PERMISSIONS

Shlyakhtenko T.N., Alyab’yeva E.A., Arzhanova O.N., Sel’kov S.A., Pluzhnicova T.A., Chepanov S.V.